In the transgenic mice models of Alzheimer's disease, a low dose of levetiracetam could alleviate cognitive decline, through suppression of proinflammatory cytokines expression and inhibition of abnormal tau hyperphosphorylation (36, 37). Here, MAPT is linked to Alzheimer disease.